These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
600 related articles for article (PubMed ID: 31571136)
41. Estimated GFR Trajectories of People Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality. Xie Y; Bowe B; Xian H; Balasubramanian S; Al-Aly Z Am J Kidney Dis; 2016 Aug; 68(2):219-228. PubMed ID: 26948835 [TBL] [Abstract][Full Text] [Related]
42. Cost-Effectiveness and Estimated Health Benefits of Treating Patients with Vitamin D in Pre-Dialysis. Snyder S; Hollenbeak CS; Kalantar-Zadeh K; Gitlin M; Ashfaq A Forum Health Econ Policy; 2020 Mar; 23(1):. PubMed ID: 32134730 [TBL] [Abstract][Full Text] [Related]
43. Cost-analysis of persistent hyperkalaemia in non-dialysis chronic kidney disease patients under nephrology care in Italy. Provenzano M; De Francesco M; Iannazzo S; Garofalo C; Andreucci M; Genualdo R; Borrelli S; Minutolo R; Conte G; De Nicola L Int J Clin Pract; 2020 May; 74(5):e13475. PubMed ID: 31909866 [TBL] [Abstract][Full Text] [Related]
44. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428 [TBL] [Abstract][Full Text] [Related]
45. Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes. Tseng CL; Lafrance JP; Lu SE; Soroka O; Miller DR; Maney M; Pogach LM BMC Nephrol; 2015 Mar; 16():34. PubMed ID: 25885708 [TBL] [Abstract][Full Text] [Related]
46. Effects of fibrates in kidney disease: a systematic review and meta-analysis. Jun M; Zhu B; Tonelli M; Jardine MJ; Patel A; Neal B; Liyanage T; Keech A; Cass A; Perkovic V J Am Coll Cardiol; 2012 Nov; 60(20):2061-71. PubMed ID: 23083786 [TBL] [Abstract][Full Text] [Related]
47. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905 [TBL] [Abstract][Full Text] [Related]
48. A systematic review of economic evaluations of screening programmes for cardiometabolic diseases. Hiligsmann M; Wyers CE; Mayer S; Evers SM; Ruwaard D Eur J Public Health; 2017 Aug; 27(4):621-631. PubMed ID: 28040737 [TBL] [Abstract][Full Text] [Related]
49. [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective]. Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; de Alvaro F; Nefrologia; 2004; 24(3):231-8. PubMed ID: 15283313 [TBL] [Abstract][Full Text] [Related]
50. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168 [TBL] [Abstract][Full Text] [Related]
51. The Kidney Failure Risk Equation for prediction of end stage renal disease in UK primary care: An external validation and clinical impact projection cohort study. Major RW; Shepherd D; Medcalf JF; Xu G; Gray LJ; Brunskill NJ PLoS Med; 2019 Nov; 16(11):e1002955. PubMed ID: 31693662 [TBL] [Abstract][Full Text] [Related]
52. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859 [TBL] [Abstract][Full Text] [Related]
53. Elderly patients with chronic kidney disease: outcomes after 5 years of follow-up. Heras M; Fernández-Reyes MJ; Sánchez R; Guerrero MT; Molina A; Rodríguez MA; Alvarez-Ude F Nefrologia; 2012 May; 32(3):300-5. PubMed ID: 22508140 [TBL] [Abstract][Full Text] [Related]
54. Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease. Perkins RM; Kirchner HL; Hartle JE; Bucaloiu ID Clin Nephrol; 2013 Oct; 80(4):256-62. PubMed ID: 23993165 [TBL] [Abstract][Full Text] [Related]